StocksMedium•13 October 2026•
1 min read
Mirum's Livmarli Hits Phase III Goals in Rare Liver Disease Study
Key Facts
1Livmarli met the primary goals of the Phase III EXPAND study for ultra-rare cholestatic liver diseases.
2The drug showed improvement in cholestatic pruritus and a reduction in serum bile acids.
3Mirum Pharmaceuticals plans to file for FDA approval of the drug in 2027.
Mirum Pharmaceuticals announced that its drug Livmarli met the primary goals of the Phase III EXPAND study for ultra-rare cholestatic liver diseases. Zacks reported that the clinical trial demonstrated improvement in cholestatic pruritus and a significant reduction in serum bile acids among patients.
The company plans to file for FDA approval of the drug in 2027 following these top-line results. This clinical milestone marks a key step for Mirum's rare disease pipeline as it moves toward regulatory submission and potential commercial expansion.